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We read with interest the CILON-T (Influence of Cilostazol-
based Triple Antiplatelet Therapy on Ischemic Complication
After Drug-Eluting Stent Implantation) trial on the efficacy of
cilostazol on ischemic complications after drug-eluting stent
(DES) implantation (1), which suggested the potential link be-
tween platelet reactivity and ischemic events in Asians.
Asians exhibit poor response to clopidogrel, maybe due to the
high prevalence of CYP2C19*2/*3 allele carriage (55% to 70%)
(1). In the CILON-T study, 50% of the patients receiving dual
antiplatelet therapy had high platelet reactivity based on Western
population (P2Y12 reaction units [PRU] 235). However, similar
to other Asian studies, the CILON-T study showed a low
ischemic events rate (2% during 6 months). In the CILON-T
study, patients under the certain PRU (210) were absent from
ischemic events (1). Meanwhile, the GRAVITAS trial demon-
strated a different threshold (175 PRU), showing the complete
immunity against 6-month thrombotic events in DES-treated
patients (2). Accordingly, we may hypothesize that Asians have
different thresholds for efficacy and safety compared to Western
populations.
Moreover, despite similar prevalence of CYP2C19*2/*3 variants
between East and South Asians, 1-week double-dose versus
standard-dose clopidogrel in acute coronary syndrome patients
showed the different ischemic events rate (3). Hypercoagulable
states are also associated with coagulation and fibrinolytic systems,
and inflammation, which are affected by environmental and
genetic factors. Differences in these components may explain
interracial disparity in the occurrence of atherothrombosis.
In the CILON-T study, platelet measures were performed 1 to
3 days after cilostazol loading. Investigators did not mention the
time interval between sampling and oral administration. Because
cilostazol reversibly inhibits platelets, its response can be more time
dependent, and the maximal effect appears later. Additionally, if a
whole blood assay (e.g., VerifyNow [Accumetrics, San Diego,
California]) is used, ex-vivo measurement can underestimate the
actual in-vivo effect of cilostazol because the red cells rapidly take
up plasma adenosine (4). Six-month clinical follow-up may be too
short to evaluate post-DES pleiotrophic effects of cilostazol.
Taken together, the CILON-T study may not be considered as
a conclusive trial, but as a starting point for new, interesting ideas.
Future trials need to include diverse ethnicity and convincing
experiments to reflect in-vivo effects of the study drug. It is hoped
that these novel concepts will assist in developing an “optimized
antiplatelet therapy.”
Young-Hoon Jeong, MD, PhD
Kevin P. Bliden, MBA
Udaya S. Tantry, PhD pIn-Suk Kim, MD, PhD
Yongwhi Park, MD, PhD
*Paul A. Gurbel, MD
*Sinai Center for Thrombosis Research
Cardiac Catheterization Laboratory
2401 West Belvedere Avenue
Baltimore, Maryland 21215
E-mail: pgurbel@lifebridgehealth.org
doi:10.1016/j.jacc.2011.02.048
EFERENCES
1. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial
evaluating the efficacy of cilostazol on ischemic vascular complications
after drug-eluting stent implantation for coronary heart disease: results
of the CILON-T (Influence of Cilostazol-based Triple Antiplatelet
Therapy on Ischemic Complication After Drug-Eluting Stent Implan-
tation) trial. J Am Coll Cardiol 2011;57:280–9.
2. Price MJ, Berger PB, Teirstein PS, et al., for the GRAVITAS
Investigators. Standard- vs high-dose clopidogrel based on platelet
function testing after percutaneous coronary intervention: the GRAVI-
TAS randomized trial. JAMA 2011;305:1097–105.
3. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus
standard-dose clopidogrel and high-dose versus low-dose aspirin in
individuals undergoing percutaneous coronary intervention for acute
coronary syndromes (CURRENT-OASIS 7). Lancet 2010;376:
1233–43.
4. Iyú D, Glenn JR, White AE, et al. Adenosine derived from ADP can
contribute to inhibition of platelet aggregation in the presence of a
P2Y12 antagonist. Arterioscler Thromb Vasc Biol 2011;31:416–22.
Reply
We cordially appreciate the interest of Dr. Jeong and colleagues in
our paper (1) and welcome their comments. The CILON-T
(Influence of Cilostazol-based Triple Antiplatelet Therapy on
Ischemic Complication After Drug-Eluting Stent Implantation)
trial was designed to compare the efficacy and safety of dual and
triple antiplatelet therapy in patients undergoing percutaneous
coronary intervention in the real-world setting (1). It showed that
the individual response to antiplatelet therapy rather than the
choice of specific regimen is important to predict future adverse
events, and it suggested the cut-off P2Y12 reaction unit (PRU)
alues in Asians, which has not been well reported.
We took comments well regarding limitations of CILON-T
rial. Cilostazol reversibly inhibits platelets, and its response can be
ore time dependent. Previous reports showed that inhibition of
denosine-diphosphate–induced platelet aggregation was signifi-
antly higher in patients receiving triple therapy than in patients
eceiving dual therapy at 24 h (2). In addition, we could find
imilar antiplatelet action of triple antiplatelet therapy at discharge
nd at 6 months. Therefore, we do not think that our sampling
iming was too early to observe the action of cilostazol.
We completely agree with Dr. Jeong and colleagues that Asians
ay have different thresholds for efficacy and safety to antiplatelet
herapy compared with the Western population. It may be partially
xplained by a high prevalence of CYP2C19*2/*3 variants. How-
ver, there seems to be discrepancy between the prevalence of high
ost-treatment platelet reactivity (PPR) and clinical events in
